214370.KQ Caregen Co.Ltd
- Market cap
- KRW 1.62T
- P/E
- -
- P/B
- 7.41x
- ROE
- 14.6%
- Dividend yield
- 1.92%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 214370.KQ undervalued?
Graham numberThe Graham number of Caregen Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Caregen Co.Ltd fundamental analysis
9 of 22 checks passedROE 1/2
Moderate return on equity (14.6%), between 10% and 20%.
ROA 1/1
Return on assets (13.3%) is above the industry median (3.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-37.6%) is not above the 5-year average (-33.7% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-37.6%) is below the industry median (6.6%).
Revenue Growth 1/2
Revenue grew 1.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (7.4x) is above the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.9%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 154.9%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Caregen Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names. The company's products are used in anti-aging, anti-pigmentatio…
Full company profileCaregen Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Caregen Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 46.8B | 57.9B | 51.2B | 64.7B | 60.3B | 59.1B | 69.1B | 79.2B | 82.6B | 72.8B | 83.0B |
| Gross Profit | 38.7B | 45.9B | 32.9B | 53.7B | 48.6B | 45.5B | 52.3B | 58.4B | 55.3B | 52.2B | 56.4B |
| Operating Income | 25.7B | 31.6B | 16.5B | 35.1B | 32.0B | 28.3B | 33.6B | 40.4B | 34.6B | 20.4B | 30.9B |
| EBITDA | - | - | - | - | - | - | 37.1B | 45.4B | 39.4B | 25.4B | 35.9B |
| Net Income | 23.0B | 24.3B | 16.5B | 28.1B | 31.5B | 25.3B | 27.3B | 39.9B | 32.3B | 20.1B | 32.0B |
| EPS | 2,166 | 2,373 | 1,624 | 2,819 | 3,210 | 516 | 555 | 813 | 660 | 411 | 655 |
| Balance Sheet | |||||||||||
| Total Assets | 249B | 247B | 219B | 232B | 217B | 227B | 234B | 247B | 241B | 231B | 241B |
| Total Liabilities | 15.0B | 15.2B | 14.2B | 14.8B | 11.4B | 17.0B | 18.1B | 20.0B | 17.7B | 18.8B | 22.6B |
| Shareholders' Equity | 234B | 232B | 205B | 217B | 205B | 210B | 216B | 227B | 223B | 212B | 219B |
| Cash & Short-term Investments | 176B | 148B | 157B | 167B | 128B | 136B | 140B | 133B | 44.3B | 8.86B | 5.90B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.9B | 47.9B | -6.82B | 69.7B | 30.8B | 51.9B | -27.7B | 28.6B | 13.5B | 18.6B | 33.6B |
| Capital Expenditure | 4.32B | 5.57B | 2.28B | 6.16B | 21.1B | 3.89B | 3.03B | 9.70B | 67.0B | 4.92B | 2.33B |
| Free Cash Flow | - | - | - | 13.5B | 8.96B | 46.6B | -30.7B | 18.9B | -53.5B | 13.7B | 31.2B |
| Ratios | |||||||||||
| ROE | 9.8% | 10.5% | 8.1% | 12.9% | 15.3% | 12.1% | 12.6% | 17.6% | 14.5% | 9.5% | 14.6% |
| ROA | 9.2% | 9.8% | 7.5% | 12.1% | 14.5% | 11.2% | 11.6% | 16.1% | 13.4% | 8.7% | 13.3% |
| Net Profit Margin | 49.0% | 42.0% | 32.2% | 43.4% | 52.2% | 42.8% | 39.5% | 50.4% | 39.1% | 27.6% | 38.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Caregen Co.Ltd dividends
- Dividend yield
- 1.92%
- Forward dividend
- -
- Payout ratio
- 154.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 31.1B | 637 | 154.9% |
| 2024 | KRW 31.4B | 642 | 97.3% |
| 2023 | KRW 28.5B | 580 | 71.4% |
| 2022 | KRW 24.5B | 499 | 89.9% |
| 2021 | KRW 20.6B | 420 | 81.3% |
| 2020 | KRW 34.7B | 3,543 | 110.4% |
| 2019 | KRW 34.7B | 3,489 | 123.8% |
| 2018 | KRW 12.3B | 1,209 | 74.5% |
| 2017 | KRW 16.4B | 1,604 | 67.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Aug 25, 2023.
Who owns Caregen Co.Ltd
- Insiders 64.07%
- Institutions 1.33%
- Public & others 34.61%
- Shares outstanding 10.7M
- Free float 2.94M
Caregen Co.Ltd company profile
- Company name
- Caregen Co.Ltd
- Ticker
- 214370.KQ
- ISIN
- KR7214370009
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 157
- Fiscal year end
- December
- Address
- Caregen Building, Anyang-Si, South Korea, 14119
- Phone
- 82 3 1420 9200
- Website
- caregen.co.kr
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names. The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications. In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face beauty treatment. Further, the company is developing cosmeceutical produts for anti-wrinkle, whitening, sun block, atopic dermatitis care, particulate matter inhibition, double chin removal, dark circle care, reduction of cellulite, sebum secretion control, and pore tightening applications; and food supplements in the areas of hangover cure, cholesterol control, and body fat lipolysis. Caregen Co., Ltd. was founded in 2001 and is based in Anyang-si, South Korea.
Caregen Co.Ltd management
2- Mr. Yongji Chung Ph.D.Chief Exec. Officer and Chief Technology Officer · born 1970
- Ms. Hui-Suk RaDirector · born 1973